Results 141 to 150 of about 2,554,026 (187)
Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]
Ann Rheum DisTedeschi SK +4 more
europepmc +1 more source
I142 Urate-lowering therapy: what is the optimum target serum urate level?
Rheumatology, 2019 openaire +1 more source
Erratum: Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]. [PDF]
J Inflamm Reseuropepmc +1 more source
Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]
Rheumatology (Oxford)europepmc +1 more source
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution
Seminars in Arthritis and Rheumatism, 2017 The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, and in some countries it is already recommended.
Lisa Stamp, Nicola Dalbeth
exaly +5 more sources
Arthritis & Rheumatology, 2022 ObjectiveTo determine whether a therapeutic approach of intensive serum urate lowering results in improved bone erosion scores in patients with erosive gout.MethodsWe undertook a 2‐year, double‐blind randomized controlled trial of 104 participants with erosive gout who were receiving serum urate–lowering therapy orally and who had serum urate levels of
Nicola Dalbeth +12 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Potential Dangers of Serum Urate-Lowering Therapy
American Journal of Medicine, 2019In observational studies, high serum urate levels are associated with adverse outcomes, including mortality. However, the hypothesis that urate-lowering may improve nongout outcomes has not been confirmed by placebo-controlled clinical trials. On the contrary, 7 recent placebo-controlled trials of urate-lowering drugs with different mechanisms of ...
Mehmet Kanbay +2 more
exaly +3 more sources
2016
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
exaly +2 more sources
Xanthine oxidase (allopurinol or febuxostat) is considered first-line urate-lowering therapy. Combination therapy with uricosuric agents may be required. The choice of urate-lowering therapy is dictated by co-morbidities, particularly renal and hepatic impairment.
exaly +2 more sources